Showing 1,281 results

Filters Content type: News, Editors' picks, About HIV Topic: New & experimental HIV treatments

News and information about clinical trials and regulatory approval of new medications to treat HIV.

New & experimental HIV treatments

Antiviral Efficacy, Safety, Tolerability of a Novel HIV-1 Maturation Inhibitor (GSK'254)

Editor's pick
Infectious Disease Advisor
31 January 2022
Pharmaceutical industry

CytoDyn board ousts CEO after a wild year, leaving an albatross of a C-suite job to fill

Editor's pick
FierceBiotech
27 January 2022
The search for a cure

Deep dive into HIV’s hidden DNA finds that some people could eventually drop their drugs

News
24 January 2022
New & experimental HIV treatments

Trials of long-acting islatravir for HIV treatment and prevention placed on hold

News
21 December 2021
Pharmaceutical industry

Merck pauses 2 more trials of backbone HIV drug over red flag, raising doubts about multi-pronged R&D strategy

Editor's pick
FierceBiotech
7 December 2021
PrEP science

Merck Announces Pause in Enrollment for Two Phase 3 Clinical Trials of Investigational, Once-Monthly, Oral Islatravir for Pre-Exposure Prophylaxis (PrEP) of HIV-1 infection

Editor's pick
BusinessWire
7 December 2021
New & experimental HIV treatments

Gilead and Merck Announce Temporary Pause in Enrolment for Phase 2 Study Evaluating an Oral Weekly Combination Regimen of Investigational Islatravir and Investigational Lenacapavir ​​​​​​​

Editor's pick
Gilead Sciences
26 November 2021
New & experimental HIV treatments

Merck pauses 'very important' HIV program after seeing red flag in phase 2 trial of once-weekly combo

Editor's pick
FierceBiotech
22 November 2021
New & experimental HIV treatments

Merck Provides Update on Phase 2 Clinical Trial of Once-Weekly Investigational Combination of MK-8507 and Islatravir for the Treatment of People Living with HIV-1

Editor's pick
Merck press release
19 November 2021
Injectable & long-acting HIV treatment

First injectable therapy for HIV approved for England and Wales

News
18 November 2021
Injectable & long-acting HIV treatment

England & Wales: NICE approves first long-acting injectable HIV-1 treatment

Editor's pick
National Institute for Health and Care Excellence
18 November 2021
Injectable & long-acting HIV treatment

Clinics will need new systems to administer injectable HIV therapies, says Canadian early adopter

News
5 November 2021
New & experimental HIV treatments

Merck's HIV program closer to regulator's doorstep with two phase 3 trials showing efficacy comparable to existing meds

Editor's pick
FierceBiotech
31 October 2021
Injectable & long-acting HIV treatment

ViiV Healthcare announces European Commission Decision for Vocabria (cabotegravir) and Rekambys (rilpivirine) injections to be initiated with or without an oral lead-in period for the long-acting treatment of HIV

Editor's pick
ViiV Healthcare
28 October 2021
Injectable & long-acting HIV treatment

Gilead and Merck Initiate Phase 2 Study Evaluating an Oral Weekly Combination Regimen of Investigational Lenacapavir and Investigational Islatravir for HIV-1 Treatment in Virologically Suppressed Adults

Editor's pick
Gilead press release
26 October 2021
New & experimental HIV treatments

Merck Announces Positive Top-Line Results from Pivotal Phase 3 Trials Evaluating Investigational, Once-Daily Oral Fixed Dose Combination of Doravirine/Islatravir for the Treatment of People with HIV-1 Infection

Editor's pick
Merck press release
25 October 2021
Injectable & long-acting HIV treatment

Cabotegravir (Vocabria®) is accepted for use within NHSScotland

Editor's pick
Scottish Medicines Consortium
11 October 2021
PrEP science

Islatravir Subdermal Implant for HIV PrEP Has Promising Phase 1 Trial

Editor's pick
Contagion Live
7 October 2021
Injectable & long-acting HIV treatment

Shionogi licenses out 3rd-gen HIV asset to ViiV

Editor's pick
FierceBiotech
28 September 2021
New & experimental HIV treatments

Exavir Therapeutics announces publication of preclinical data for novel tenofovir prodrug, XVIR-210, in Nature Communications, demonstrating long-acting exposures sufficient for antiviral activity against HIV and HBV

Editor's pick
GlobeNewswire
20 September 2021
PrEP science

First-in-Class NRTTI Demonstrates Potential as Long-Acting Oral PrEP Against HIV

Editor's pick
Contagion Live
13 September 2021
New & experimental HIV treatments

CytoDyn’s previous HIV filing snafu now on better course after FDA sets them straight

Editor's pick
Fierce Biotech
16 August 2021
Antibody-based prevention

HIV vaccines and immunotherapies “would be further along” if they had the resources of COVID-19, says leading antibody researcher

News
28 July 2021
The search for a cure

Novel dual antibody therapy partially controls virulent HIV infection in monkeys off treatment

News
23 July 2021